The company's catheter-based Cardiac Pulmonary Nerve Stimulation (CPNS) System electrically stimulates the autonomic cardiac nerves to increase contractility of the heart, resulting in improved cardiac output, renal blood flow, urine production, and pharmacological tolerance. By decreasing negative hormonal signaling and improving in-hospital morbidity and mortality, Cardionomic's neuromodulation treatment addresses a large unmet need for patients suffering from acute decompensated heart failure (ADHF). The company has successfully demonstrated human feasibility of the physiological mechanism behind its device in multiple investigational clinical studies.